Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1–2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients’ Satisfaction of Multiple Surgeries
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Inclusion/Exclusion Criteria
2.2. Data Collection and Statistical Analysis
2.3. Endpoints of the Study and Statistical Analysis
2.4. Surgical Technique
2.5. Questionnaire
3. Results
3.1. General Features
3.2. Surgical Technique
3.3. Complications
3.4. Questionnaire
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Modesitt, S.C.; Lu, K.; Chen, L.-M.; Powell, C.B. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet. Gynecol. 2017, 130, e110–e126. [Google Scholar]
- Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, 359–386. [Google Scholar] [CrossRef] [PubMed]
- King, M.C.; Marks, J.H.; Mandell, J.B. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302, 643–646. [Google Scholar] [CrossRef] [PubMed]
- Struewing, J.P.; Hartge, P.; Wacholder, S.; Baker, S.M.; Berlin, M.; McAdams, M.; Timmerman, M.M.; Brody, L.C.; Tucker, M.A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 1997, 336, 1401–1408. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007, 25, 1329–1333. [Google Scholar] [CrossRef] [Green Version]
- Antoniou, A.; Pharoah, P.D.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117–1130. [Google Scholar] [CrossRef] [Green Version]
- Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.A.; Mooij, T.M.; Roos-Blom, M.J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017, 317, 2402–2416. [Google Scholar] [CrossRef] [Green Version]
- Daly, M.B.; Pilarski, R.; Yurgelun, M.B.; Berry, M.P.; Buys, S.S.; Dickson, P.; Domchek, S.M.; Elkhanany, A.; Friedman, S.; Garber, J.E.; et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw. 2020, 18, 380–391. [Google Scholar] [CrossRef]
- Nelson, H.D.; Fu, R.; Goddard, K.; Mitchell, J.P.; Okinaka-Hu, L.; Pappas, M.; Zakher, B. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation; Evidence Synthesis No. 101. AHRQ Publication No. 12-05164-EF-1; Agency for Healthcare Research and Quality: Rockville, MD, USA, December 2013. [Google Scholar]
- Meijers-Heijboer, H.; van Geel, B.; van Putten, W.L.; Henzen-Logmans, S.C.; Seynaeve, C.; Menke-Pluymers, M.B.; Bartels, C.C.; Verhoog, L.C.; Ouweland, A.M.V.D.; Niermeijer, M.F.; et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2001, 345, 159–164. [Google Scholar] [CrossRef]
- Hartmann, L.C.; Sellers, T.A.; Schaid, D.J.; Frank, T.S.; Soderberg, C.L.; Sitta, D.L.; Frost, M.H.; Grant, C.S.; Donohue, J.H.; Woods, J.E.; et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 2001, 93, 1633–1637. [Google Scholar] [CrossRef] [Green Version]
- Costa, M.; Saldanha, P. Risk Reduction Strategies in Breast Cancer Prevention. Eur. J. Breast Health 2017, 13, 103–112. [Google Scholar] [CrossRef] [PubMed]
- Matan, L.S.; Perri, T.; Kogan, L.; Brandt, B.; Meyer, R.; Levin, G. Ovarian cancer risk management in BRCA-mutation carriers: A comparison of six international and national guidelines. Eur. J. Obstet. Gynecol. Reprod. Biol. 2022, 278, 166–171. [Google Scholar] [CrossRef] [PubMed]
- Batista, L.I.; Lu, K.H.; Beahm, E.K.; Arun, B.K.; Bodurka, D.C.; Meric-Bernstam, F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer 2008, 8, 101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Willsher, P.; Ali, A.; Jackson, L. Laparoscopic oophorectomy in the management of breast disease. ANZ J. Surg. 2008, 78, 670–672. [Google Scholar] [CrossRef]
- Casey, W.J., 3rd; Rebecca, A.M.; Andres, L.A.; Craft, R.O.; Smith, A.A.; Pockaj, B.A. Safety and efficacy of perforator flap breast reconstruction with combined intraabdominal procedures. Ann. Plast Surg. 2010, 64, 144–150. [Google Scholar] [CrossRef]
- Beatson, G.T. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2, 104–107. [Google Scholar] [CrossRef] [Green Version]
- Perri, T.; Levin, G.; Naor-Revel, S.; Eliassi-Revivo, P.; Lifshitz, D.; Friedman, E.; Korach, J. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study. Int. J. Gynaecol. Obstet. 2022, 157, 431–436. [Google Scholar] [CrossRef]
- Metcalfe, K.; Lynch, H.T.; Foulkes, W.D.; Tung, N.; Kim-Sing, C.; Olopade, O.I.; Eisen, A.; Rosen, B.; Snyder, C.; Gershman, S.; et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015, 1, 306–313. [Google Scholar] [CrossRef]
- Francis, P.A.; Regan, M.M.; Fleming, G.F.; Láng, I.; Ciruelos, E.; Bellet, M.; Bonnefoi, H.R.; Climent, M.A.; Da Prada, G.A.; Burstein, H.J.; et al. Adjuvant ovarian suppression in premenopausal breast cancer. SOFT Investigators, International Breast Cancer Study Group. N. Engl. J. Med. 2015, 372, 436–446. [Google Scholar] [CrossRef] [Green Version]
- Heemskerk-Gerritsen, B.A.; Seynaeve, C.; van Asperen, C.J.; Ausems, M.G.; Collee, J.M.; van Doorn, H.C.; Rookus, M.A. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: Revisiting the evidence for risk reduction. Hereditary Breast and Ovarian Cancer Research Group Netherlands. J. Natl. Cancer Inst. 2015, 107, djv033. [Google Scholar] [CrossRef] [Green Version]
- Perabò, M.; Fink, V.; Günthner-Biller, M.; von Bodungen, V.; Friese, K.; Dian, D. Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: A novel surgical approach to female BRCA-mutation carriers. Arch. Gynecol Obstet. 2014, 289, 1325–1330. [Google Scholar] [CrossRef] [PubMed]
- Del Corral, G.A.; Wes, A.M.; Fischer, J.P.; Serletti, J.M.; Wu, L.C. Outcomes and cost analysis in high-risk patients undergoing simultaneous free flap breast reconstruction and gynecologic procedures. Ann. Plast Surg. 2015, 75, 534–538. [Google Scholar] [CrossRef] [PubMed]
- Ma, I.T.; Gray, R.J.; Wasif, N.; Butler, K.A.; Cornella, J.L.; Magrina, J.F.; Magtibay, P.M.; Casey, W.J.; Mahabir, R.; Rebecca, A.M.; et al. Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery. Ann. Surg. Oncol. 2017, 24, 77–83. [Google Scholar] [CrossRef] [PubMed]
- Yueh, J.H.; Slavin, S.A.; Adesiyun, T.; Nyame, T.T.; Gautam, S.; Morris, D.J.; Tobias, A.M.; Lee, B.T. Patient satisfaction in postmastectomy breast reconstruction: A comparative evaluation of DIEP, TRAM, latis-simus flap, and implant techniques. Plast. Reconstr. Surg. 2010, 125, 1585–1595. [Google Scholar] [CrossRef]
- Jagsi, R.; Jiang, J.; Momoh, A.O.; Alderman, A.; Giordano, S.H.; Buchholz, T.A. Complications after mastectomy and immediate breast reconstruction for breast cancer: A claims-based analysis. Ann. Surg. 2016, 263, 219–227. [Google Scholar] [CrossRef] [Green Version]
- Saccardi, C.; Zovato, S.; Spagnol, G.; Bonaldo, G.; Marchetti, M.; Alessandrini, L.; Tognazzo, S.; Guerriero, A.; Vitagliano, A.; Laganà, A.S.; et al. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC). Gynecol. Oncol. 2021, 163, 364–370. [Google Scholar] [CrossRef] [PubMed]
- Buzzaccarini, G.; Török, P.; Vitagliano, A.; Petousis, S.; Noventa, M.; Hortu, I.; Giannini, A.; Laganà, A.S. Predictors of Pain Development after Laparoscopic Adnexectomy: A Still Open Challenge. J. Investig. Surg. 2022, 35, 1392–1393. [Google Scholar] [CrossRef]
- Grandi, G.; Sammarini, M.; Cortesi, L.; Toss, A.; Botticelli, L.; Varliero, F.; Sighinolfi, G.; Barbieri, E.; Facchinetti, F. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: A prospective study. Menopause 2021, 28, 263–270. [Google Scholar] [CrossRef]
BRCA 1 Carriers (n = 32) | BRCA 2 Carriers (n = 22) | Total (n = 54) | |
---|---|---|---|
Mean Age at surgery | 45 (35–72) | 47 (42–63) | 46 (35–72) |
Patients without Breast Cancer | 15 (27.7%) | 11 (20.4%) | 26 (48.1%) |
Patients with current and/or recurrent Breast Cancer | 17 (31.5%) | 11 (20.4%) | 28 (51.9%) |
Menopausal Status | |||
Pre-menopausal | 21 (38.9%) | 9 (16.7%) | 30 (55.6%) |
Post-menopausal | 11 (20.4%) | 13 (24.1%) | 24 (44.5%) |
Familiarity | |||
Ovarian Cancer | 18 (33.3%) | 9 (16.7%) | 27 (50.0%) |
Breast Cancer | 19 (35.2%) | 18 (33.3%) | 37 (68.5%) |
Negative | 3 (5.6%) | 4 (7.4%) | 7 (13.0%) |
BRCA 1 Carriers (n = 32) | BRCA 2 Carriers (n = 22) | Total (n = 54) | |
---|---|---|---|
Breast surgery: Bilateral Mastectomy | 28 (51.8%) | 19 (35.2%) | 47 (87.0%) |
RRBM | 14 (25.9%) | 8 (14.8%) | 22 (40.7%) |
Therapeutic | 14 (25.9%) | 11 (20.4%) | 25 (46.3%) |
Immediate reconstruction with implant | 25 (46.3%) | 16 (29.6%) | 41 (75.9%) |
With axillary staging | 14 (25.9%) | 7 (13.0%) | 21 (38.9%) |
Breast surgery: Unilateral Mastectomy | 4 (7.4%) | 3 (5.6%) | 7 (13.0%) |
Prophylactic | 1 (1.8%) | 3 (5.6%) | 4 (7.4%) |
Therapeutic | 3 (5.6%) | 0 | 3 (5.6%) |
Immediate reconstruction with implant | 3 (5.6%) | 3 (5.6%) | 6 (11.2%) |
With axillary staging | 2 (3.7%) | 0 | 2 (3.7%) |
Gynecologic surgery | |||
RRSO | 28 (51.9%) | 20 (37.0%) | 48 (88.9%) |
RRSO + LH | 4 (7.4%) | 2 (3.7%) | 6 (11.2%) |
Total (n = 54) | |
---|---|
Median operative time mastectomy + RRSO, min | 232 (150–283) |
Median operative time RRSO, min | 46 (32–60) |
Median operative time mastectomy + RRSO + LTH, min | 278 (200–345) |
Median operative time RRSO + LH, min | 105 (90–140) |
Median hospital stays, days | 3 (1–9) |
Total Patients (n = 54) | |
---|---|
Intraoperative complications | 0 |
Total Postoperative complications <30 days | 10 (18%) |
Breast Postoperative complications <30 days | 9 (16.6%) |
Non-infectious reconstructive complication with removal expander/implant | 1 (1.9%) |
Infectious reconstructive complications with removal expander/implant | 3 (5.6 %) |
Infectious reconstructive complications without removal expander/implant | 1 (1.9%) |
Breast hematoma requiring evacuation | 2 (3.7%) |
Breast seroma aspiration | 1 (1.9%) |
Fever and Skin infection | 1 (1.9%) |
Gynecology Postoperative complications <30 days | 1 (1.9%) |
Trocar hematoma | 1 (1.9%) |
Total Postoperative complications >30 days | 0 |
Question 1 | Very unsatisfied | Unsatisfied | Neutral | Satisfied | Very satisfied | |
Answers n (%) | 42 (77%) | 7 (13%) | 2 (3%) | 3 (7%) | 0 | |
Question 2 | Yes | No | ||||
Answers n (%) | 3 (5%) | 51 (95%) | ||||
Question 3 | Not very much | Not much | Neutral | Much | Very much | |
Answers n (%) | 42 (77%) | 7 (13%) | 4 (8%) | 0 | 1 (2%) | |
Question 4 | Yes | No | ||||
Answers n (%) | 6 (12%) | 48 (88%) | ||||
Question 5 | Yes | No | ||||
Answers n (%) | 50 (92%) | 4 (8%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Saccardi, C.; Spagnol, G.; Saibene, T.; De Lorenzo, L.S.; Marchetti, M.; Bonaldo, G.; Michieletto, S.; Toffanin, M.C.; Noventa, M.; Tozzi, R. Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1–2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients’ Satisfaction of Multiple Surgeries. J. Clin. Med. 2022, 11, 7502. https://doi.org/10.3390/jcm11247502
Saccardi C, Spagnol G, Saibene T, De Lorenzo LS, Marchetti M, Bonaldo G, Michieletto S, Toffanin MC, Noventa M, Tozzi R. Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1–2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients’ Satisfaction of Multiple Surgeries. Journal of Clinical Medicine. 2022; 11(24):7502. https://doi.org/10.3390/jcm11247502
Chicago/Turabian StyleSaccardi, Carlo, Giulia Spagnol, Tania Saibene, Luciana Serena De Lorenzo, Matteo Marchetti, Giulio Bonaldo, Silvia Michieletto, Maria Cristina Toffanin, Marco Noventa, and Roberto Tozzi. 2022. "Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1–2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients’ Satisfaction of Multiple Surgeries" Journal of Clinical Medicine 11, no. 24: 7502. https://doi.org/10.3390/jcm11247502
APA StyleSaccardi, C., Spagnol, G., Saibene, T., De Lorenzo, L. S., Marchetti, M., Bonaldo, G., Michieletto, S., Toffanin, M. C., Noventa, M., & Tozzi, R. (2022). Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1–2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients’ Satisfaction of Multiple Surgeries. Journal of Clinical Medicine, 11(24), 7502. https://doi.org/10.3390/jcm11247502